| 6923- | Flav, | Flavonoids: an overview |
| - | Review, | Nor, | NA |
| 6876- | Flav, | Flavonoid-rich orange juice is associated with acute improvements in cognitive function in healthy middle-aged males |
| - | Trial, | AD, | NA |
| 4250- | Flav, | Dietary Flavonoids Interaction with CREB-BDNF Pathway: An Unconventional Approach for Comprehensive Management of Epilepsy |
| - | Review, | AD, | NA |
| 4063- | Flav, | VitB12, | VitB6, | Homocysteine and Dementia: An International Consensus Statement |
| - | Review, | AD, | NA |
| 4060- | Flav, | Vitamin Supplementation and Dementia: A Systematic Review |
| - | Review, | AD, | NA |
| 2401- | Flav, | In vitro effects of some flavonoids and phenolic acids on human pyruvate kinase isoenzyme M2 |
| - | in-vitro, | Nor, | NA |
| 2313- | Flav, | Flavonoids against the Warburg phenotype—concepts of predictive, preventive and personalised medicine to cut the Gordian knot of cancer cell metabolism |
| - | Review, | Var, | NA |
| 2642- | Flav, | QC, | Api, | KAE, | MCT | In Vitro–In Vivo Study of the Impact of Excipient Emulsions on the Bioavailability and Antioxidant Activity of Flavonoids: Influence of the Carrier Oil Type |
| - | in-vitro, | Nor, | NA | - | in-vivo, | Nor, | NA |
| 6929- | FLS, | AudGS, | Multisensory gamma stimulation promotes glymphatic clearance of amyloid |
| - | in-vivo, | AD, | NA |
| 6931- | FLS, | Gamma frequency sensory stimulation in mild probable Alzheimer's dementia patients: Results of feasibility and pilot studies |
| - | Trial, | AD, | NA |
| 6930- | FLS, | 40 Hz light flickering facilitates the glymphatic flow via adenosine signaling in mice |
| - | in-vivo, | Nor, | NA |
| 6934- | FLS, | 40 Hz light flicker stimulation for neurodegenerative diseases: Mechanisms and clinical perspectives |
| - | Review, | AD, | NA | - | Review, | Park, | NA |
| 6933- | FLS, | AudGS, | Gamma sensory stimulation in mild Alzheimer's dementia: An open-label extension study |
| - | Trial, | AD, | NA |
| - | Trial, | AD, | NA |
| 6943- | FLS, | Promoting glymphatic flow: A non-invasive strategy using 40 Hz light flickering |
| - | Review, | AD, | NA |
| 4121- | FLS, | Sensory-Evoked 40-Hz Gamma Oscillation Improves Sleep and Daily Living Activities in Alzheimer’s Disease Patients |
| - | Trial, | AD, | NA |
| 4108- | FLS, | Improvement of olfactory function in AD mice mediated by immune responses under 40 Hz light flickering |
| - | in-vivo, | AD, | NA |
| 4107- | FLS, | Ex, | Combined effects of aerobic exercise and 40-Hz light flicker exposure on early cognitive impairments in Alzheimer's disease of 3×Tg mice |
| - | in-vivo, | AD, | NA |
| 6990- | Form, | Formononetin induces apoptosis of human osteosarcoma cell line U2OS by regulating the expression of Bcl-2, Bax and MiR-375 in vitro and in vivo |
| - | vitro+vivo, | OS, | U2OS |
| 6978- | Form, | Formononetin promotes angiogenesis through the estrogen receptor alpha-enhanced ROCK pathway |
| - | vitro+vivo, | Nor, | HUVECs |
| 6979- | Form, | Pharmacokinetics and Bioavailability of the Isoflavones Formononetin and Ononin and Their in Vitro Absorption in Ussing Chamber and Caco-2 Cell Models |
| - | in-vitro, | Colon, | Caco-2 |
| 6980- | Form, | The potential role of formononetin in cancer treatment: An updated review |
| - | Review, | Var, | NA |
| 6981- | Form, | Formononetin: a review of its source, pharmacology, drug combination, toxicity, derivatives, and drug delivery systems |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | PSA, | NA |
| 6982- | Form, | Formononetin: A Review of Its Anticancer Potentials and Mechanisms |
| - | Review, | Var, | NA |
| 6983- | Form, | Formononetin enhances angiogenesis in diabetic wounds by inhibiting ferroptosis through suppression of mtROS-mediated xCT/GPX4 upregulation |
| - | vitro+vivo, | Nor, | HUVECs | - | vitro+vivo, | Diabetic, | NA |
| 6984- | Form, | Formononetin suppresses colitis-associated colon cancer by targeting lipid synthesis and mTORC2/Akt signaling |
| - | in-vitro, | Colon, | HCT116 | - | Review, | IBD, | RAW264.7 |
| 6985- | Form, | Formononetin relieves the facilitating effect of lncRNA AFAP1-AS1-miR-195/miR-545 axis on progression and chemo-resistance of triple-negative breast cancer |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | BT549 |
| 6986- | Form, | Anti-angiogenesis Function of Ononin via Suppressing the MEK/Erk Signaling Pathway |
| - | in-vitro, | Var, | NA |
| 6987- | Form, | Formononetin exhibits anticancer activity in gastric carcinoma cell and regulating miR-542-5p |
| - | vitro+vivo, | GC, | SGC-7901 | - | in-vitro, | BC, | MGC803 |
| 6988- | Form, | Formononetin ameliorates high glucose‑induced endothelial dysfunction by inhibiting the JAK/STAT signaling pathway |
| - | in-vitro, | Nor, | HUVECs |
| - | in-vitro, | Nor, | HUVECs |
| 6991- | Form, | Formononetin-induced apoptosis of human prostate cancer cells through ERK1/2 mitogen-activated protein kinase inactivation |
| - | in-vitro, | Pca, | LNCaP | - | in-vitro, | Pca, | PC3 |
| 6992- | Form, | Formononetin: pharmacological properties and therapeutic potential |
| - | Review, | Nor, | NA |
| 6970- | Form, | Formononetin, an isoflavone from Astragalus membranaceus inhibits proliferation and metastasis of ovarian cancer cells |
| - | in-vitro, | Ovarian, | NA |
| 6997- | Form, | PI, | Formononetin–piperine–phospholipid complex: enhancement of anti-osteoporotic activity and bioavailability in bone marrow in rats |
| - | in-vivo, | ostP, | NA |
| 6996- | Form, | MET, | Formononetin and metformin act synergistically to inhibit growth of MCF-7 breast cancer cells in vitro |
| - | in-vitro, | BC, | MCF7 |
| 6995- | Form, | Formononetin inhibits neuroinflammation and increases estrogen receptor beta (ERβ) protein expression in BV2 microglia |
| - | Review, | Nor, | BV2 |
| 6993- | Form, | ISL, | Novel herbal flavonoids promote apoptosis but differentially induce cell cycle arrest in human colon cancer cell |
| - | in-vitro, | CRC, | HCT116 |
| 6976- | Form, | Study on the Mechanism of Formononetin Against Hepatocellular Carcinoma: Regulating Metabolic Pathways of Ferroptosis and Cell Cycle |
| - | vitro+vivo, | HCC, | HepG2 |
| 6963- | Form, | Formononetin-induced apoptosis by activation of Ras/p38 mitogen-activated protein kinase in estrogen receptor-positive human breast cancer cells |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | T47D |
| 6964- | Form, | Formononetin induces cell cycle arrest of human breast cancer cells via IGF1/PI3K/Akt pathways in vitro and in vivo |
| - | vitro+vivo, | BC, | MCF7 |
| 6965- | Form, | Formononetin inhibits colon carcinoma cell growth and invasion by microRNA‑149‑mediated EphB3 downregulation and inhibition of PI3K/AKT and STAT3 signaling pathways |
| - | in-vitro, | CRC, | HCT116 |
| 6966- | Form, | Formononetin-induced oxidative stress abrogates the activation of STAT3/5 signaling axis and suppresses the tumor growth in multiple myeloma preclinical model |
| - | vitro+vivo, | MM, | NA |
| 6967- | Form, | BTZ, | Formononetin Regulates Multiple Oncogenic Signaling Cascades and Enhances Sensitivity to Bortezomib in a Multiple Myeloma Mouse Model |
| - | in-vivo, | Melanoma, | U266 | - | in-vivo, | Melanoma, | RPMI-8226 |
| 6968- | Form, | Formononetin represses cervical tumorigenesis by interfering with the activation of PD-L1 through MYC and STAT3 downregulation |
| - | in-vitro, | Cerv, | NA |
| 6969- | Form, | Formononetin inhibits tumor growth by suppression of EGFR-Akt-Mcl-1 axis in non-small cell lung cancer |
| - | vitro+vivo, | NSCLC, | HCC827 | - | in-vitro, | NSCLC, | A549 | - | in-vitro, | Lung, | H1299 |
| 6977- | Form, | Differential ability of formononetin to stimulate proliferation of endothelial cells and breast cancer cells via a feedback loop involving MicroRNA-375, RASD1, and ERα |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | BT474 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | HUVECs |
| 6971- | Form, | In vitro and in vivo anti-cancer activity of formononetin on human cervical cancer cell line HeLa |
| - | vitro+vivo, | Cerv, | HeLa |
| 6972- | Form, | PacT, | Formononetin ameliorates the drug resistance of Taxol resistant triple negative breast cancer by inhibiting autophagy |
| - | in-vivo, | BC, | MDA-MB-231 |
| 6973- | Form, | Formononetin enhances the chemosensitivity of triple negative breast cancer via BTB domain and CNC homolog 1-mediated mitophagy pathways |
| - | Human, | BC, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid